
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Certain Patients with High-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC)
Dateline City: KENILWORTH, N.J. Application Based on Results from Phase 2 KEYNOTE-057 Trial, to be…





.jpg)










.jpg)





